Psychiatric and behavioral symptoms associated with Alzheimer's disease-such as anger, agitation, aggression, and paranoid thoughts and ideas-may improve with the use of second-generation antipsychotic medications, a new federally funded study has found. Improvements were seen both in global measures and in measures of specific symptoms. In addition, the analysis indicates that particular symptoms may respond better to different second-generation antipsychotic medications.
The new analysis of data from the Clinical Antipsychotic Trials of Intervention Effectiveness-Alzheimer's Disease (CATIE-AD), funded by the National Institute of Mental Health, will be published online ahead of print by The American Journal of Psychiatry (AJP), the official journal of the American Psychiatric Association. The report will appear online1 under AJP in Advance on June 2, and will appear in print in the July issue of AJP.
READ MORE @ MEDICAL NEWS TODAY